Business Context and Reporting Period
This Form 8-K was filed by Astro-Med, Inc. (referred to as Astronova, Inc. in metadata) on March 4, 2010. The report details a specific corporate transaction regarding executive compensation rather than periodic financial results.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the repurchase of stock options:
- Total Cash Outlay: $219,553 ($131,732 to Mr. Pizzuti and $87,821 to Mr. O'Connell).
- Shares Involved: 171,875 total options (103,125 for Mr. Pizzuti; 68,750 for Mr. O'Connell).
- Option Exercise Price: $5.4546 per share.
- Pricing Basis: Closing stock price on March 3, 2010, less a 10% discount, minus the exercise price.
Material Changes
The material change reported is the Company's repurchase of vested stock options held by two senior executives prior to their expiration on March 20, 2010. This transaction reduces the number of outstanding options and results in an immediate cash payment to the executives.
Management Commentary and Governance
The purchase of the options was reviewed and approved by the Company's Compensation and Audit Committees. The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies beyond the specific transaction details.
Investor Verification Checklist
- Verify the closing stock price of Astro-Med, Inc. on March 3, 2010, to confirm the calculation of the purchase price.
- Confirm the total number of outstanding options remaining after this repurchase.
- Review the Company's most recent 10-K or 10-Q for context on overall liquidity and cash reserves relative to this $219,553 expenditure.
- Check for any subsequent filings regarding the employment status of Mr. Pizzuti and Mr. O'Connell following this transaction.